{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:18:29Z","timestamp":1789244309858,"version":"build-2803163510"},"reference-count":33,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2024.12660","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T10:44:17Z","timestamp":1721731457000},"source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of telitacicept in patients with lupus nephritis"],"prefix":"10.3892","volume":"28","author":[{"given":"Hong","family":"Zhu","sequence":"first","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qian","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Wei","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Kun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou University, Lishui, Zhejiang 323000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"key20240906093030_b1-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.intimp.2019.03.010","article-title":"Therapeutic advances in the treatment of SLE","volume":"72","author":"Mohamed","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"e000389","key":"key20240906093030_b2-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"key":"key20240906093030_b3-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00296-017-3733-2","article-title":"Treatment for lupus nephritis: An overview of systematic reviews and meta-analyses","volume":"37","author":"Chen","year":"2017","journal-title":"Rheumatol Int"},{"key":"key20240906093030_b4-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: Core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"key20240906093030_b5-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"40","key":"key20240906093030_b6-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12010040","article-title":"Altered germinal-center metabolism in B cells in autoimmunity","volume":"12","author":"Shiraz","year":"2022","journal-title":"Metabolites"},{"key":"key20240906093030_b7-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"601","key":"key20240906093030_b8-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00520-y","article-title":"Adding belimumab improves lupus nephritis","volume":"16","author":"Onuora","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"key20240906093030_b9-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"key20240906093030_b10-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20240906093030_b11-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"key20240906093030_b12-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"key20240906093030_b13-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"key20240906093030_b14-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: A real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"key20240906093030_b15-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/BOR.0000000000000740","article-title":"New classification criteria for systemic lupus erythematosus","volume":"32","author":"Aringer","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"key20240906093030_b16-ETM-28-4-12660","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2022","journal-title":"J Rheumatol"},{"key":"key20240906093030_b17-ETM-28-4-12660"},{"issue":"16039","key":"key20240906093030_b18-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.39","article-title":". Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"key20240906093030_b19-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5694\/mja16.01229","article-title":"Systemic lupus erythematosus: An update","volume":"206","author":"Golder","year":"2017","journal-title":"Med J Aust"},{"key":"key20240906093030_b20-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0961203308090029","article-title":"Current treatment of lupus nephritis","volume":"17","author":"Houssiau","year":"2008","journal-title":"Lupus"},{"key":"key20240906093030_b21-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/eye.2016.298","article-title":"Hydroxychloroquine retinopathy","volume":"31","author":"Yusuf","year":"2017","journal-title":"Eye (Lond)"},{"issue":"10291","key":"key20240906093030_b22-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210291","article-title":"The effect of calcineurin inhibitors on MMPs activity in heart and their side effects-a review of literature","volume":"24","author":"Sur\u00f3wka","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20240906093030_b23-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/bjophthalmol-2018-313350","article-title":"Early hydroxychloroquine retinopathy: Optical coherence tomography abnormalities preceding Humphrey visual field defects","volume":"103","author":"Garrity","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"key20240906093030_b24-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs. piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: A randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"issue":"CD002922","key":"key20240906093030_b25-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922.pub4","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","volume":"6","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"key20240906093030_b26-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bpobgyn.2019.10.008","article-title":"Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus","volume":"64","author":"Kado","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"key20240906093030_b27-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.healun.2007.10.012","article-title":"Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients","volume":"27","author":"Galiwango","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"key20240906093030_b28-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/BOR.0000000000000527","article-title":"Glucocorticoids and antimalarials in systemic lupus erythematosus: An update and future directions","volume":"30","author":"Ugarte","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"key20240906093030_b29-ETM-28-4-12660","first-page":"90","article-title":"OP0137 Efficacy And Safety Of Telitacicept, A Novel Blys\/April Dual Inhibitor, In Patients With Systemic Lupus Erythematosus: A phase 3, randomized, placebo-controlled 52-week study","volume":"82","author":"Wang","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"key20240906093030_b30-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.34067\/KID.0000000000000230","article-title":"Management of lupus nephritis: New treatments and updated guidelines","volume":"4","author":"Avasare","year":"2023","journal-title":"Kidney360"},{"key":"key20240906093030_b31-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int Rep"},{"key":"key20240906093030_b32-ETM-28-4-12660","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: Results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"e515","key":"key20240906093030_b33-ETM-28-4-12660","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.515","article-title":"B cell pathway dual inhibition for systemic lupus erythematosus: A prospective single-arm cohort study of telitacicept","volume":"5","author":"Ji","year":"2024","journal-title":"MedComm"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:30:40Z","timestamp":1725604240000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2024.12660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2024.12660","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"article-number":"371"}}